Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

UK fraud office liaising with China on GSK bribery case

Published 07/23/2014, 12:39 PM
Updated 07/23/2014, 01:00 PM
UK fraud office liaising with China on GSK bribery case

UK fraud office liaising with China on GSK bribery case

By Kirstin Ridley LONDON (Reuters) - Britain's fraud office is working with authorities in China in a first for such Anglo-Chinese cooperation as it carries out its own investigation into alleged corruption at drugmaker GlaxoSmithKline (L:GSK).

"Certainly, so far as I am aware it is the first time we have had cooperation with the Chinese on an SFO case," David Green, the head of the Serious Fraud Office (SFO), said in an interview with Reuters on Wednesday.

Green, who said he had visited China earlier this year, said the Chinese government had a clear interest in rooting out bribery and corruption although it might have "slightly different perspectives" than the SFO.

The SFO launched a formal criminal investigation into Britain's biggest drugmaker in May, posing a new challenge to the company, which has been accused by Chinese police of funneling up to 3 billion yuan ($480 million) in bribes to encourage doctors to use its medicines.

The SFO action came less than two weeks after Chinese police announced on May 14 that they had charged the former British boss of GSK's China business and other colleagues with corruption.

The U.S. Department of Justice is also investigating GSK for possible breaches of the Foreign Corrupt Practices Act, which prohibits payments to government officials, including state-employed doctors, to obtain business overseas.

Britain's relatively new Bribery Act also prohibits such overseas bribes.

Since the case in China blew up in July last year, allegations of GSK bribery have surfaced in other countries and GSK is now investigating claims that bribes were also paid to doctors in Poland, Iraq, Jordan and Lebanon.

Green said the SFO was looking into GSK's behavior in a number of jurisdictions, including Europe and the Middle East. In many cases, the facts behind the allegations have still to be established - and his office has asked for assistance from whistleblowers.

"Suffice to say we have a number of sources of information," Green said.

GSK Chief Executive Andrew Witty has described the allegations in China as "shameful". However, he declined to comment in detail about the case when questioned by reporters after presenting second-quarter results.

"I remain very concerned about allegations concerning our China business. The situation is complicated and difficult and while the investigation is active there is little I can add," Witty said.

© Reuters. David Green, director of the Serious Fraud Office (SFO), gestures during an interview with Reuters in London

(Additional reporting by Ben Hirschler; Editing by Mark Potter)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.